Reserpine

Reserpine
	Black Box Warning
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gerald Chi

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

Title

See full prescribing information for complete Boxed Warning.

ConditionName:

Content

Overview

Reserpine is a catecholamine-depleting sympatholytic that is FDA approved for the {{{indicationType}}} of mild essential hypertension. There is a Black Box Warning for this drug as shown here. Common adverse reactions include abdominal pain, diarrhea, nausea, vomiting, xerostomia, dizziness, headache, lethargy, somnolence, vertigo, depression, and nasal congestion.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Condition1

Dosing Information

Dosage

Condition2

Dosing Information

Dosage

Condition3

Dosing Information

Dosage

Condition4

Dosing Information

Dosage

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1

Developed by:

Class of Recommendation:

Strength of Evidence:

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Reserpine in adult patients.

Non–Guideline-Supported Use

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Reserpine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding FDA-Labeled Use of Reserpine in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1

Developed by:

Class of Recommendation:

Strength of Evidence:

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Reserpine in pediatric patients.

Non–Guideline-Supported Use

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Reserpine in pediatric patients.

Contraindications

Condition1

Warnings

Title

See full prescribing information for complete Boxed Warning.

ConditionName:

Content

Description

Precautions

Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Reserpine in the drug label.

Central Nervous System

Cardiovascular

Respiratory

Gastrointestinal

Hypersensitivity

Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Reserpine in the drug label.

Central Nervous System

Cardiovascular

Respiratory

Gastrointestinal

Hypersensitivity

Miscellaneous

Drug Interactions

Drug

Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Pregnancy Category

Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Reserpine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Reserpine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Reserpine with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Reserpine with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Reserpine with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Reserpine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Reserpine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Reserpine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Reserpine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Reserpine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Reserpine in patients who are immunocompromised.

Administration and Monitoring

Administration

Oral

Intravenous

Monitoring

There is limited information regarding Monitoring of Reserpine in the drug label.

Condition1

Description

IV Compatibility

There is limited information regarding IV Compatibility of Reserpine in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

Description

Management

Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Reserpine in the drug label.

Pharmacology


Reserpine
Systematic (IUPAC) name
Methyl (3β,16β,17α,18β,20α)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate
Identifiers
CAS number	50-55-5
ATC code	C02AA02
PubChem	5770
DrugBank	DB00206
Chemical data
Formula	Template:OrganicBox atom Template:OrganicBox atom Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox atom Template:OrganicBox Template:OrganicBox atom Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox
Mol. mass	608.68 g/mol
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	50%
Metabolism	gut/liver
Half life	phase 1 = 4.5h, phase 2 = 271h, average = 33h
Excretion	62% feces / 8% urine
Therapeutic considerations
Licence data	US
Pregnancy cat.	C Risk cannot be ruled out, US
Legal status	Rx-only (some countries banned/discontinued)
Routes	oral

Mechanism of Action

Structure

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Reserpine in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Reserpine in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Reserpine in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Reserpine in the drug label.

Condition1

Description

How Supplied

Storage

There is limited information regarding Reserpine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Reserpine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Reserpine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Reserpine in the drug label.

Precautions with Alcohol

Alcohol-Reserpine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Resa®

Serpalan®^[1]

Look-Alike Drug Names

N/A^[2]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

↑ "RESERPINE tablet".
↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Reserpine
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage=
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Reserpine
 |Label Name=No image.jpg

}}

[1] "RESERPINE tablet".

[www.ismp.org-2] "http://www.ismp.org". External link in |title= (help)

[1]

[2]